Impact of Potentially Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective Cohort Study. by Wallace, Emma et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
General Practice Articles Department of General Practice
1-2-2017
Impact of Potentially Inappropriate Prescribing on
Adverse Drug Events, Health Related Quality of
Life and Emergency Hospital Attendance in Older
People Attending General Practice: A Prospective
Cohort Study.
Emma Wallace
Royal College of Surgeons in Ireland, emmawallace@rcsi.ie
Ronald McDowell
Royal College of Surgeons in Ireland, ronaldmcdowell@rcsi.ie
Kathleen Bennett
Royal College of Surgeons in Ireland, kathleenebennett@rcsi.ie
Tom Fahey
Royal College of Surgeons in Ireland, tomfahey@rcsi.ie
Susan M. Smith
Royal College of Surgeons in Ireland, susansmith@rcsi.ie
This Article is brought to you for free and open access by the Department
of General Practice at e-publications@RCSI. It has been accepted for
inclusion in General Practice Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of Potentially Inappropriate Prescribing on Adverse Drug Events,
Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective
Cohort Study. The journals of gerontology. Series A, Biological sciences and medical sciences. 2017;72(2):271-277.
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/gpart/113
© The Author 2016. Published by Oxford University Press on behalf of The Gerontological Society of America.
271
Journals of Gerontology: Medical Sciences
cite as: J Gerontol A Biol Sci Med Sci, 2017, Vol. 72, No. 2, 271–277
doi:10.1093/gerona/glw140
Advance Access publication July 27, 2016
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For 
commercial re-use, please contact journals.permissions@oup.com
Research Article
Impact of Potentially Inappropriate Prescribing on Adverse 
Drug Events, Health Related Quality of Life and Emergency 
Hospital Attendance in Older People Attending General 
Practice: A Prospective Cohort Study
Emma  Wallace,1 Ronald  McDowell,1 Kathleen  Bennett,2 Tom  Fahey,1 and 
Susan M. Smith1
1HRB Centre for Primary Care Research and 2Population Health Sciences Division, Royal College of Surgeons of Ireland (RCSI), Dublin, 
Ireland.
Address correspondence to Emma Wallace, PhD, HRB Centre for Primary Care Research, RCSI Medical school, 123 St Stephen’s Green, Dublin 
2, Ireland. E-mail: emmawallace@rcsi.ie
Received March 14, 2016; Accepted July 6, 2016
Decision Editor: Stephen Kritchevsky, PhD 
Abstract
Background: Potentially inappropriate prescribing (PIP) describes medications where risk generally outweighs benefit for older people. Cross-
sectional studies suggest an association between PIP and poorer health outcomes but there is a paucity of prospective cohort studies. This study 
investigates the longitudinal association of PIP with adverse drug events (ADEs), health related quality of life, and accident & emergency visits.
Methods: Study design: Two-year (2010–2012) prospective cohort study (n = 904, ≥70 years, community-dwelling) with linked pharmacy 
dispensing data. Exposure: Baseline PIP: Screening Tool for Older Persons potentially Inappropriate Prescriptions (STOPP) and Beers 2012 
applied 12 months prior. Study outcomes: ADEs (patient interview), health related quality of life (EQ-5D-3L: patient questionnaire), and 
accident & emergency visits (general practice medical record review). Statistical analysis: Descriptive statistics: Poisson (incidence rate ratio 
[95% confidence interval [CI]], linear regression models [regression coefficient [95% CI]], and logistic [odds ratio [OR] [95% CI]).
Results: Of 791 participants eligible for follow-up, 673 (85%) returned a questionnaire and 605 (77%) also completed an ADE interview. 
Baseline STOPP PIP prevalence was 40% and 445 (74%) patients reported ≥1 ADE at follow-up. In multivariable analysis, ≥2 STOPP PIP was 
associated with ADEs (adjusted incidence rate ratio: 1.29 [95% CI 1.03, 1.85; p = .03]; poorer health related quality of life [adjusted regression 
coefficient: −0.11 [95% CI −0.16, −0.06; p < .001]]; and, ≥1 accident & emergency visit [adjusted OR: 1.85 [95% CI 1.06, 3.24; p = .03]]). 
Baseline Beers 2012 prevalence was 26% and there was no association with adverse health outcomes in multivariable analysis.
Conclusions: Older community-dwelling people, prescribed ≥2 STOPP PIP are more likely to report ADEs, poorer health related quality of life 
and attend the accident & emergency department over 2-year follow-up.
Keywords: Adverse drug events—Potentially inappropriate prescribing—Community-dwelling
Research indicates that approximately one-fifth of all primary care pre-
scriptions are potentially inappropriate, where risk generally outweighs 
the benefit (1). Explicit prescribing criteria such as the Screening Tool 
for Older Persons potentially Inappropriate Prescriptions (STOPP) and 
the American Geriatrics Society Beers 2012 criteria have been devel-
oped to identify potentially inappropriate prescribing (PIP) (2,3). The 
65 STOPP criteria include drug–drug interactions, optimal dose and 
duration of treatment, and appropriate clinical indication. Developed 
through Delphi consensus in Ireland and the United Kingdom, STOPP 
has been validated across different care settings in several European 
countries (4). The Beers 2012 criteria include 53 drugs to avoid in older 
people and have been widely validated internationally (3).
However, if these criteria are to have clinical utility in primary 
care, it is important to establish if PIP are associated with adverse 
health outcomes such as adverse drug events (ADEs). Older peo-
ple are particularly vulnerable to these events due to their altered 
pharmacokinetic profile and higher levels of polypharmacy (5,6). 
A  recent systematic review reported an ADE-admission rate of 
10.7% in older people (7). The impact of PIP on ADEs and other 
important outcomes, such as health related quality of life (HRQoL) 
and emergency hospital attendance, is unclear. Existing research 
has methodological limitations, in particular a paucity of prospec-
tive cohort studies, and has focused largely on inpatient and nursing 
home populations, with very few general practice studies (8–11).
The aim of this study is to investigate the longitudinal association 
of PIP, as defined by the STOPP and Beers 2012 criteria, with ADEs, 
HRQoL, and emergency hospital attendance in older (≥70  years) 
community-dwelling people followed up for 2 years.
Methods
The Strengthening The Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines were adhered to in the conduct 
and reporting of this study (12). A more detailed description of the 
methods is presented in Supplementary File 1.
Study Design and Study Population
This is a 2-year prospective cohort study of older general practice 
(GP) patients recruited from 15 practices in the Republic of Ireland 
(2010–2012). At baseline (2010), a proportionate stratified random 
sampling approach was used to recruit patients for study participa-
tion (10). Study inclusion criteria were: (i) aged ≥70 years on January 
1, 2010 and; (ii) in receipt of a valid general medical services (GMS) 
card. Exclusion criteria are presented in Supplementary File 1. Each 
participant’s GP determined eligibility for participation at baseline 
and at follow-up (2012). Ethical approval for this study was granted 
by the Royal College of Surgeons in Ireland (RCSI) Human Research 
Ethics committee.
Exposure: PIP
PIP was identified by applying the STOPP criteria (version-1) and the 
Beers 2012 (Supplementary Tables 1 and 2) to pharmacy claims data 
by linkage to the national Health Services Executive (HSE)-Primary 
Care Reimbursement Scheme (PCRS) pharmacy claims database. 
Baseline measurement of PIP (12  months prior) and confounding 
variables were included in the regression models as predictor vari-
ables (Supplementary Figure 1). A comparison of baseline PIP and 
PIP at follow-up (using the period of 12 months prior to the ADE 
interview at follow-up) indicated that PIP had remained relatively 
stable over time for both sets of prescribing indicators (see Table 1 
and Supplementary Figure 2).
Primary Outcome: ADE
Patient interviews (November 2012 to June 2013) were conducted 
to identify patient-reported ADEs that had occurred over the pre-
vious 6 months (see Supplementary File 1 for a detailed explana-
tion of the ADE interview). In addition, GP medical records were 
reviewed to identify any additional ADEs in the same time period 
(Supplementary Figure 1). All patient-reported ADEs were indepen-
dently reviewed by two academic GPs, blinded to the prescribing 
criteria, who independently rated the likelihood of each patient-
reported ADE being a true ADE on a Likert scale (13). Only ADEs 
where both reviewers rated the ADE as likely (≥50% likelihood) 
were included. These ADEs were then reviewed by an academic GP 
and academic pharmacist who rated each in terms of severity (mild, 
moderate or severe and/or life-threatening,) based on a previously 
utilized classification system (14,15). Inter-rater reliability was deter-
mined using the kappa statistic.
Secondary Outcomes: HRQoL and Emergency 
Hospital Attendance
HRQoL was measured using the Euro Quol-5 Dimensions 
(EQ-5D)-3L, administered via postal questionnaire. Emergency hos-
pital attendance was measured by reviewing the GP medical record 
regarding emergency admissions and accident & emergency (A&E) 
visits.
Confounder Variables
Potential confounders were determined a priori and recorded at 
baseline from the GP medical record (age, gender, comorbidity), by 
linkage to the HSE-PCRS pharmacy claims database (number of pre-
scribed medication classes, medication possession ratio) and from 
the postal questionnaire (social class, education, deprivation, vulner-
ability, depression and/or anxiety, and social support).
Statistical Methods
All statistical analysis was completed using Stata version-13 (StataCorp, 
College Station, TX). Descriptive statistics were calculated. A multi-
variable Poisson regression model was used to investigate the associa-
tion between count of ADEs per patient at follow-up and exposure to 
PIP at baseline (no PIP, one PIP, ≥2 PIP), with adjustment for potential 
confounders. Multilevel unadjusted and adjusted incidence rate ratios 
(95% confidence intervals [CIs], p-value) were calculated.
Multilevel linear regression was used to examine how EQ-5D 
utility at follow-up varied by exposure to PIP, adjusting for con-
founders. Multilevel unadjusted and adjusted β-coefficients were 
calculated. Emergency hospital attendance was examined in relation 
to ≥1 A&E visits and ≥1 emergency admissions in the 2-year follow-
up period, adjusting for relevant confounders. A multilevel logistic 
regression model calculated unadjusted and adjusted odds ratios 
(95% CIs, p value).
Methodological Quality Assessment
The Cochrane risk of bias tool for non-randomized studies was used 
to assess the overall risk of bias of this prospective cohort study (16).
Results
Study Population
Of 904 baseline patients, 113 met ≥1 exclusion criteria at 2-year 
follow-up (Figure 1). Of 791 eligible participants, 605 (76.5%) com-
pleted both the ADE interview and postal questionnaire. For the 
GP medical record review, 859 (95%) baseline study participants 
were reviewed. Reasons for non-review were: 19 moved practice; 14 
moved into a nursing home; nine medical record reviews were miss-
ing; and, three were long-term hospital inpatients.
Study Participants’ Socio-demographic 
Characteristics
For the primary outcome of ADE, a total of 286 (47%) were male. The 
mean age was 77 years, median age was 79 years (Inter Quartile Range 
76, 83) and the majority were classified as skilled in terms of social 
class (n = 473, 78%). Patients were largely of White Irish background 
(97.4%), with 2.6% (n  = 16) from another Caucasian background. 
Table 1 presents the descriptive statistics for the study population.
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Exposure to PIP as Defined by the Beers 2012 
Criteria
A total of 35 (66%) of the Beers 2012 criteria were applied. At 
baseline, 450 (74%) participants were prescribed no PIP, 96 (16%) 
one PIP and 62 (10%) ≥2 PIP. The most frequently prescribed PIP 
indicators are presented in Supplementary Table 3. Benzodiazepines, 
antipsychotics and non-COX selective non-steroidal anti-inflamma-
tory drugs (NSAIDs) were the frequently prescribed. In multivariable 
analysis ≥2 Beers 2012 PIP was not associated with ADEs (adjusted 
incidence rate ratio 1.00 [95% CI 0.78, 1.29]), poorer HRQOL 
(adjusted coefficient −0.05 [95% CI −0.11, 0.003]), A&E visits 
(adjusted OR 1.54 [95% CI 0.88, 2.71]) or emergency admission 
(adjusted OR 0.72 [95% CI 0.41, 1.28]) (Supplementary Table 4).
The remainder of this results section focuses on the impact of PIP 
identified by the STOPP criteria on subsequent adverse health outcomes.
Exposure to PIP as Defined by the STOPP Criteria
A total of 51 (78%) of the 65 STOPP criteria were applied. There 
was inadequate clinical information to apply 14 criteria. At baseline, 
the prevalence of ≥1 PIP was 40% (n = 243), with 362 (60%) par-
ticipants prescribed no PIP, 142 (24%) one PIP and 101 (16%) ≥2 
PIP. The 10 most frequently prescribed STOPP PIP are presented in 
Supplementary Table 5. The three most frequently prescribed were 
proton pump inhibitors for peptic ulcer disease at maximum thera-
peutic dosage for more than 8 weeks, calcium channel clockers pre-
scribed to patients with chronic constipation and long-term use of 
NSAIDs for pain relief.
Primary Outcome: ADE
At follow-up, 428 (71%) of 605 participants reported ≥1 ADE 
during the 6-month outcome measurement period. An additional 
17 participants (2.8%) had an ADE recorded in their GP medical 
record, that was not reported by the participant. Of the 445 (74%) 
participants with ≥1 ADE, 96 (16%) reported one ADE, 94 (16%) 
reported two, 64 (11%) reported three, 52 (9%) reported four, 38 
(6%) reported five, 101 (17%) reported ≥6 ADEs. The median num-
ber of ADEs was 2 (Inter Quartile Range 0, 4).Thirty percent of 
patient-reported symptoms were established as an ADE after inde-
pendent review. Inter-rater agreement was 94% and the kappa statis-
tic was 0.87 (95% CI 0.85, 0.90). The majority (n = 424, 95.2%) of 
ADEs were rated as mild in terms of severity with inter-rater agree-
ment of 84%. The remainder were rated as moderate (n = 11, 2.5%) 
and severe and/or life threatening (n  =  10, 2.3%). Of 10 severe 
ADEs, nine resulted in emergency hospital admission. No recorded 
ADE resulted in death.
Table 1. Study Participants’ Descriptive Statistics for Primary Out-
come ADE
Baseline (n = 904) Follow-up (n = 605)
Median (IQR) Median (IQR)
Age 77 (74, 81) 79 (76, 83)
Deprivation 1.49 (−0.6, 3.1) 1.36 (−0.64, 2.88)
Number of drug classes 6 (3,8) 6 (4,8)
Medication Possession 
Ratio
0.83 (0.69, 0.91) 0.87 (0.77, 0.94)
Gender Number (%) Number (%)
 Male 415 (46) 286 (47)
 Female 489 (54) 319 (53)
Marital status*
 Married 403 (45) 275 (45)
  Separated and/or 
divorced
45 (5) 29 (5)
 Widowed 293 (32) 199 (33)
  Never married and/
or single
162 (18) 102 (17)
Living arrangements†
  Husband and/or wife 
and/or partner
393 (44) 249 (42)
  Family and/or 
relatives
116 (13) 73 (12)
 Live alone 343 (38) 240 (40)
 Other 40 (5) 33 (6)
Education‡
 Basic education 555 (61) 355 (59)
  Upper and post- 
secondary
343 (38) 247 (41)
Social class
 Unskilled 342 (38) 132 (22)
 Skilled 562 (62) 473 (78)
Charlson comorbidity index§
 0 358 (40) 252 (41)
 ≥1 544 (60) 353 (59)
Number of STOPP PIP
 0 526 (58) 323 (53)
 1 215 (24) 157 (26)
 ≥2 163 (18) 125 (21)
Number of Beers PIP
 0 450 (74) 466 (77)
 1 96 (16) 115 (19)
 ≥2 59 (10) 24 (4)
Notes: ADE = adverse drug event; IQR = Inter Quartile Range; PIP = po-
tentially inappropriate prescribing; STOPP = Screening Tool for Older Persons 
potentially Inappropriate Prescriptions.
*Marital status missing n = 1 (baseline).
†Living arrangements missing n = 1 (baseline), n = 10 (follow-up).
‡Education missing n = 3 (follow-up).
§Charlson missing n = 2 (baseline).
Figure 1. Flow of patients: prospective cohort study (2010–2012).
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The main medication classes associated with ADEs and the main 
adverse effects reported by patients are presented in Supplementary 
Table 6. The commonest ADEs according to drug classes were: (i) 
antithrombotic agents (n = 243, 41%) associated with easy bruis-
ing, difficulty stopping a small cut bleeding and indigestion and/or 
heartburn; (ii) diuretics (n = 162, 27%) associated with getting up at 
night to urinate, passing urine more often and dry mouth; and, (iii) 
beta-blockers (n = 145, 24%) associated with cold hands and feet, 
fatigue and dizziness.
Poisson Multilevel Regression Model Examining the 
Effect of PIP on ADEs
In unadjusted regression analysis, compared to no PIP, ≥2 STOPP 
PIP was associated with increasing numbers of ADEs at follow-up 
(unadjusted incidence rate ratio 2.27 (95% CI 1.83, 2.81), p < .001). 
While this association diminished when adjusted for confounders, it 
remained statistically significant (adjusted incidence rate ratio 1.29 
(95% CI 1.03, 1.60), p = .03) (Table 2). The number of drug classes, 
comorbidity and deprivation were also all independently associated 
with this outcome.
Secondary Outcomes: HRQoL
A total of 673 participants completed the EQ-5D at follow-up. Eleven 
(1.6%) had missing data and so were excluded resulting in 662 included 
in the statistical analysis. Median participant EQ-5D utility was 0.80 
(Inter Quartile Range 0.66, 1). In multilevel linear regression analysis, 
adjusted for confounders, there was a statistically significant reduction 
in EQ-5D utility β-coefficient for patients with ≥2 PIP of −0.11 (−0.16, 
−0.06), p < .001) (Table 2). Other variables, independently associated 
with this outcome, were increasing age and vulnerability.
Secondary Outcomes: A&E Visits and Emergency 
Hospital Admission
A total of 806 participants had available A&E visits and emergency 
admission data. In logistic regression analysis, following adjustment 
for confounders, one PIP (adjusted OR 1.82 [95% CI 1.15, 2.89], 
p = .01) and ≥2 PIP (adjusted OR 1.85 [95% CI 1.06, 3.24], p = .03) 
were significantly associated with an increased odds of patients attend-
ing A&E at least once over the 2-year follow-up period (Table 2).
A total of 199 (25%) participants had ≥1 emergency admission 
recorded during follow-up. Of these 136 (17%) participants had 
one emergency admission, 44 (5%) two and 19 (2%) ≥3 emergency 
admissions. Following adjustment for confounders, ≥2 PIP was not 
associated with emergency admission (adjusted OR 1.00 [95% 
CI 0.63, 1.61], p  =  .99). The number of drug classes at baseline, 
deprivation and previous emergency hospital attendance were all 
independently associated with this outcome.
Methodological Quality Assessment
A summary is presented in Table 3. Overall; the risk of bias was low 
with an overall response rate of 76.5% for all three outcome meas-
urements which is considered very high.
Discussion
Principal Findings
The prevalence of patient-reported ADEs was 74%, most frequently 
easy bruising, urinary frequency, ankle swelling, fatigue, and muscle 
pains. The majority (95%) were considered to be clinically mild. There 
was a modest longitudinal association between ≥2 STOPP PIP and 
increasing numbers of ADEs, clinically important poorer HRQoL and 
these patients were almost twice as likely to attend the A&E depart-
ment. There was no association with emergency admission which is 
unsurprising considering the small number of ADE-related admissions 
(n = 9) recorded in this study. It would be interesting to examine this 
outcome in a larger sample with more power to answer this specific 
question. Overall, this study found no association between Beers PIP 
and ADEs, poorer HRQoL or emergency hospital attendance.
According to one review, the minimally important difference for 
the EQ-5D (ie, the change in score that is clinically meaningful) was 
0.074 (ranging from −0.011 to 0.140) (17). This suggests that the 
association of PIP on HRQoL reported in this adjusted analysis of 
−0.11 is likely to be clinically important. It may be postulated that 
ADEs considered mild by clinicians (eg, easy bruising, urinary fre-
quency, muscle pains) have an adverse impact on patients’ HRQoL. 
Poorer HRQoL can also have important implications for future 
health; one study that recruited 439 older people from two health 
systems reported that a reduction in EQ-5D of 0.05 increased the 
risk of death at 5-year follow-up (18).
Context of This Research in Comparison With 
Previous Literature
Explicit measures of PIP and future ADEs
A recent cross-sectional study in Sweden (n = 813, aged ≥65 years) 
demonstrated an association between STOPP PIP and ADEs (PIP 
vs no PIP: 2.47 [95% CI 1.65, 3.69]) (8). In 2010, a retrospective 
Irish cohort study (n = 931, aged ≥70 years) reported an association 
between patients taking ≥2 STOP PIP and ADEs (OR ≥2 PIP vs no 
PIP: 2.21 [1.02, 4.83]) (10). Similar studies examining the impact of 
the Beers criteria on ADEs have had mixed results, with one study 
Table 2. Statistical Analysis: STOPP PIP and Adverse Health Outcomes Regression Models
ADEs† HRQoL (EQ-5D)‡ ≥1 ED Visits§ ≥1 Emergency Admission§
Adjusted IRR, 95% CI Adjusted Coefficient, 95% CI Adjusted OR, 95% CI Adjusted OR, 95% CI
1 PIP 0.85 (0.70, 1.03) −0.002 (−0.04, 0.04) 1.82 (1.15, 2.89)* 0.88 (0.59, 1.31)
≥2 PIP 1.29 (1.03, 1.60)* −0.11 (−0.16, −0.06)** 1.85 (1.06, 3.24)* 1.00 (0.63, 1.61)
Notes: STOPP PIP exposure at baseline, adjusted for confounders. Outcomes: ADEs, HRQoL (EQ-5D), ED visits, emergency admission.
ADE = adverse drug event; CI = confidence interval; HRQoL = health related quality of life; IQR = Inter Quartile Range; OR = odds ratio; PIP = potentially 
inappropriate prescribing; STOPP = Screening Tool for Older Persons potentially Inappropriate Prescriptions.
†Adjusted for age, gender, deprivation, education, social class, number of medications, comorbidity, and medication adherence.
‡Additionally adjusted for vulnerability, social support, and depression.
§Additionally adjusted for vulnerability and prior healthcare utilization.
*p < .05, **p < .001.
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demonstrating an association (9,11). The current study builds on 
existing research by demonstrating a longitudinal association with 
STOPP PIP and ADEs for older people attending GP.
A recent inpatient Italian study (n = 871, ≥65 years) reported that 
the prescription of ≥2 STOPP PIP was associated with future ADEs 
(adjusted OR 2.36 [95% CI 1.10, 5.06]), while the same number of 
Beers 2003 PIP was not (adjusted OR 2.15 [95% CI 0.90, 5.14]) 
(19). In Ireland, a prospective A&E study (n = 600, ≥65 years) com-
pared the measurement of PIP with STOPP and the 2003 Beers cri-
teria in predicting subsequent ADEs at 4-month follow-up (20). The 
prescription of ≥1 STOPP PIP was associated with ADEs (adjusted 
ORs 1.85 [95% CI 1.51, 2.26]) while ≥1 Beers 2003 PIP was not 
(adjusted OR 1.28 [95% CI 0.95, 1.72]) (20).
Two large-scale retrospective studies using older iterations of the 
Beers criteria did not demonstrate any association between Beers PIP 
and ADEs. In a retrospective cohort study (n = 5,152 aged ≥65 years) of 
patients admitted to 81 hospitals in Italy between 1997 and 1998 use 
of Beers 2003 PIP was not associated with ADEs or mortality (21). In a 
French study (n = 2,018 aged ≥70 years) of patients admitted to a single 
acute geriatric unit Beers 1997 PIP was not associated with ADEs (22). 
The current study did not demonstrate any association between PIP 
identified by the Beers 2012 and subsequent adverse health outcomes. 
However, it’s important to note that due to international variations 
in prescribing practices and medication availability, several of the U.S. 
Beers criteria were not applicable in this study setting. In addition, the 
prevalence of patients prescribed at ≥1 Beers 2012 PIP was lower at 
26% compared to 40% prescribed ≥1 STOPP PIP.
PIP and other adverse health outcomes
In Ireland, a retrospective cohort study reported a statistically signifi-
cant association between ≥2 STOPP PIP and poorer EQ-5D scores 
(adjusted β −0.09 [SE 0.02]) (10). The current study adds to this 
limited previous research by demonstrating a clinically significantly 
reduction in HRQoL in older people taking ≥2 STOPP PIP over 
time. Previous research examining PIP and healthcare utilization 
has focused on other care settings with methodological limitations. 
A U.S. retrospective cohort study of older community-dwelling peo-
ple (n = 17,971) reported that ≥1 PIP increased the odds of a hospi-
tal admission (OR 1.99, 95% CI 1.76, 2.26) and emergency room 
visits (OR 1.98, 95% CI 1.77, 2.20) compared to no PIP (23). In a 
second U.S. study (n = 7,594, ≥65 years) patients receiving nursing 
home care and prescribed ≥1 PIP were more likely to be hospitalized 
(adjusted OR 1.27; 95% CI, 1.10, 1.46) and to die (adjusted OR 
1.46; 95% CI, 1.31, 1.62) (24).
Strengths and Limitations
This cohort study was carefully conducted adhering to the STROBE 
reporting guidelines. Methodological quality assessment indicates 
that the risk of bias is low. Use of linked national pharmacy claims 
data adds to the robustness of the calculation of the exposure variable 
(PIP) and confounder variables (eg, number of prescribed medication 
classes). Previous studies have often relied on self-report medication 
use which may not be as accurate, especially in older populations (25). 
ADEs were ascertained by a detailed patient interview and correspond-
ing GP medical record review. All reported ADEs were independently 
reviewed and verified by two academic GPs, blinded to the prescrib-
ing criteria. In addition, each ADE was assessed regarding severity. 
A corresponding review of each study participant’s GP medical record 
allowed for accurate recording of both comorbidity and emergency 
hospital attendance. As a result, this study was able to include several 
confounders in statistical analysis that were not included in previous 
studies such as medication adherence, deprivation and social support.
There are several limitations. First, this study included 15 GPs in 
one region of Ireland and as such may not be generalizable to other 
settings. A subset of the STOPP and Beers 2012 could not be applied 
to the pharmacy claims database due to inadequate clinical informa-
tion. However, this issue is common to previous studies conducted 
in this area (26). The prevalence of reported ADEs was high (74%) 
when compared to previous studies, which ranged from 4.2% to 
62% (27). However, previous community-based research has usually 
depended on patient self-report surveys to ascertain ADEs, rather 
than the symptom-based interview and medical record review uti-
lized for this study (11,27). In addition, reported ADE prevalence at 
follow-up was broadly similar to that reported at baseline (78%), 
which used an identical process of ADE measurement (10).
Clinical and Future Research Implications
With increasing levels of multimorbidity and associated polyphar-
macy, optimizing safe prescribing for older people will be a key chal-
lenge for prescribers into the future. This study indicates that STOPP 
PIP has an independent association, beyond that of polypharmacy 
alone, with adverse health outcomes for older people.
One difficulty in deprescribing is the lack of evidence-based 
guidance to support this process, and the issue of clinical guidelines 
adopting a “single disease” focus that do not take the realities of multi-
morbidity and polypharmacy into account (28). Other barriers include 
concern about stopping medications started by different clinicians and 
knowledge gaps regarding which medications should be prioritized 
for cessation (29). Explicit prescribing criteria such as STOPP that are 
Table 3. Methodological Quality Assessment of the Prospective Cohort Study
Methodological Quality Criteria Definitely Yes Probably Yes Probably No Definitely No
Was selection of exposed and non-exposed cohorts drawn from the same 
population?
*
Can we be confident in the assessment of the exposure? *
Can we be confident that the outcome of interest was not present at the start of the 
study?
*
Did the study match exposed and unexposed for all variables that are associated 
with the outcome of interest or did the statistical analysis adjust for these prognostic 
variables?
*
Can we be confident in the assessment of presence or absence of prognostic factors? *
Can we be confident in the assessment of the outcome? *
Was the follow-up of the cohort adequate? *
Were co-interventions similar between groups? *
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linked to future adverse health outcomes offer a useful and evidence-
based tool for clinicians to support medication reviews and deprescrib-
ing decisions. There is some randomized controlled trial evidence to 
support this approach. A recent Irish primary care randomized con-
trolled trial (n = 196 patients aged ≥70 years) used the STOPP crite-
ria to identify PIP and then implemented a multifaceted intervention 
involving pharmacist-led academic detailing and GP-led medication 
reviews supported by a web-based algorithm (30). This reduced PIP at 
6-month follow-up (% with no PIP; intervention arm 47.5% vs con-
trol arm 22.7%: OR 3.1 95% CI 1.4, 6.5, number needed to treat 
[NNT] = 4) but was largely due to dose reduction or cessation of pro-
ton pump inhibitors (30). Another trial of 400 hospitalized patients 
aged ≥65 years which used screening with the STOPP and/or START 
criteria followed by recommendations to participants’ attending physi-
cians as the intervention, reduced PIP significantly at hospital discharge 
and 6-month follow up (absolute risk reduction 35.7%) (31).
Finally, as new evidence emerges drugs that were once considered 
potentially inappropriate may no longer be, highlighting the impor-
tance of revising prescribing indicators sets regularly. The STOPP 
criteria have recently been updated to reflect this and future studies 
should aim to use the most up to date version (32).
Conclusions
This study indicates that PIP identified using the STOPP criteria 
are associated with future ADEs, poorer HRQoL and A&E visits 
in older community-dwelling people. While there will be a clinical 
indication for a proportion of medications identified as potentially 
inappropriate, the STOPP criteria offer an evidence-based support 
for prescribers in conducting medication reviews for older people.
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